Business Results for Fiscal 2022 and Earnings Forecast for Fiscal 2023
Director, and CFO
Muneki Handa
Agenda
01
FY 2022 Business Results Overview
2
Roadmap for the Realization of the TSUMURA VISION
"Cho-WA" 2031
1st stage
FY2022-2024
-Germination-
2nd stage
FY2025-2027
-Growth-
3rd stage
FY2028-2031
-Flowering-
Prescription Kampo
Products
Standardization of Kampo treatments
Personalized Kampo treatments
Over 50% physicians write 10 or more Kampo prescriptions
50% of physicians write basic |
prescriptions in all treatment areas |
R&D
Personalized Kampo
treatmentsResearch Scientific study of pre-
symptomatic diseases
Development
Social
implementation
Chinese
operations
Formulation
platform
Crude drug
platform
Research
platform
Traditional Chinese medical products business
Crude drugs, drug pieces and Yakushokudogen products
Traditional Chinese Medicine Research Center
Market
entry
Sales
expansion
Establishment
Build
foundations
Establish brands
Function
expansion
Establish brands
Lead industry development
Evidence-building for traditional
Chinese medical products
Smart factory
Expand scope of
automation
Shift to oversight/management
Realize smart factories
Labor
productivity
Sales
Production
Crude drugs
Sales per MR (Yen/MR)
Physical labor productivity
Personnel expenses per crude drug arranging volume
Double productivity | |
(vs. FY2021) | 3 |
FY2022 Business Results Overview
【Million yen】 | FY 2022 | FY 2022 | Achievement | YoY | |
Plan | Results | ||||
rate | Amount | Change | |||
Sales | 138,500 | 140,043 | 101.1% +10,497 | +8.1% | |
Domestic business | 124,300 | 124,698 | 100.3% | － | － |
China business | 14,200 | 15,345 | 108.1% | － | － |
Operating profit | 20,800 | 20,916 | 100.6% | (1,460) | (6.5)% |
Domestic business | 21,200 | 21,190 | 100.0% | － | － |
China business | (400) | (273) | － | － | － |
Ordinary profit | 21,200 | 23,453 | 110.6% | (2,451) | (9.5)% |
Profit | 15,000 | 16,482 | 109.9% | (2,354) | (12.5)% |
attributable to owners of parent | |||||
PL translation rate (CNY) | 19.50 | 19.55 | － | +2.51 | － |
*Forex rate at the time overseas subsidiaries' PLs were incorporated; differs from the import rate for raw material crude drugs
Ratio to total sales
Prescription
Kampo Products
85.2%
External sales by consolidated subsidiaries 11.6%
OTC Kampo etc 2.9%
Other prescription pharmaceuticals 0.3%
4
Key Points in Performance
Achieved plans for sales and at each profit level.
Net sales | 140,043 million yen Achievement rate 101.1% YoY +8.1% |
◼ Domestic business | Total sales for the 129 prescription Kampo products: 119,362 million yen, rose 4.6% year-on-year |
Total sales of the OTC Kampo formulations and other healthcare products: 3,966 million yen, grew 3.2% year-on-year
- China business sales: 15,345 million yen
Operating profit | 20,916 | million yen | Achievement rate | 100.6% | YoY | (6.5)% |
Operating profit margin | 14.9 | % | vs. Plan | (0.1)pt | YoY | (2.4)pt |
- Cost-to-salesratio: 51.2％, up 0.8pt vs. plan and a rise of 2.5pt year-on-year;
Versus plan: Mainly due to negative impact from soaring energy and raw material expenses
◼ SG&A ratio: 33.8%, down 0.8pt vs. plan and a fall of 0.2pt year-on-year;
Versus plan: Implemented cost control in response to a rise in cost-to-sales that outperformed the plan
Ordinary profit | 23,453 million yen Achievement rate 110.6% YoY (9.5)% |
- Foreign exchange gain primarily related to loans to overseas subsidiaries: 1,508 million yen, down 965 million yen year-on-year;foreign exchange impact
Profit attributable to | 16,482 million yen Achievement rate | 109.9% YoY | (12.5)% | |
owners of parent | ||||
◼ Extraordinary income: Refund margin owing to a reduction in paid-in capital at affiliates: 463 million yen | ||||
◼ Extraordinary loss: Impairment loss in tandem with revision to construction plans for the Traditional Chinese Medicine Research | 5 | |||
Center: 597 million yen |